What is the latest market price of pimoteb in 2025?

Pimitespib As a new typeHSP90 inhibitor, it has gradually shown its unique value in the current field of anti-tumor treatment. It is primarily indicated for patients with gastrointestinal stromal tumors (GISTs) whose disease has progressed after chemotherapy, a tumor type that has received widespread attention due to its specific biomarkers and treatment difficulty. The dosage regimen of pimistebi is 160 mg orally per day. It is recommended to take it on an empty stomach. It should be followed a cycle of five days of medication followed by two days of non-medication. Patients can adjust the dosage appropriately according to their physical condition. This approach to medication largely reflects the trend of personalized medicine, allowing treatments to better meet the specific needs of patients.

In the international market, pimetibib has attracted widespread attention from clinicians and patients, but it has not yet been approved for marketing in China, so domestic patients cannot purchase the drug through formal channels. Currently, patients can only rely on purchasing drugs overseas to obtain pimetibib. In overseas markets, especially in Japan, the original drug specification of pimotebi is 40mg*40 tablets, and each box sells for about more than 10,000 yuan. Taking into account factors such as the drug's R&D costs, production process, and market supply and demand, this price reflects its importance in the anti-tumor field and the scarcity of the drug.

The mechanism of pimetibib is based on its inhibitory effect on heat shock protein90 (HSP90), which plays a key role in the growth and survival of various cancer cells. By inhibiting HSP90, pimetibi can promote the degradation of related transcription factors and signaling pathways, thereby interfering with the growth and proliferation of tumor cells. The advantage of this targeted therapy is that it has relatively low side effects. Compared with traditional chemotherapy drugs, pimetibi can focus on attacking cancer cells without significantly damaging normal cells.

Reference materials:https://www.mt-pharma.co.jp/e/company/rd/pipe/